The Future of Life-saving Treatments

We aim to reduce the world's organ shortage and speed up drug development by providing accessible life science solutions.
About us
Business areas

Automated Laboratory Workflows Through Bioconvergence

Learn how synergies between our technologies enable laboratories to develop new drugs faster and more cost efficient.

Learn more

What is bioconvergence?

Bico by numbers

  • Net sales Jan-Sep 2022
    0 MSEK
  • Organic growth Jan-Sep 2022
    0 %
  • Employees
    0 +
  • Instruments in the field
    0 +
  • Publications
    0 +
  • Countries
    0 +
Investor relations
Investor Relations

Products that Fuel Groundbreaking Scientific Discoveries

Learn more

Trusted By Your Favorite Treatment Provider
View customer stories
Foto: Felix Groteloh
Foto: Felix Groteloh
CYTENA_116_By_Felix_Groteloh
06 kopiera
_MG_1296 kopiera
DSC_7861 kopiera
20 kopiera
lab_16 (1) kopiera
IMG_7983 (1)
covid-19-bico
bico-people
bico-biosciences-hero

BICO News Feed​

November 25, 2022
Cellink Uppsala University and CELLINK sent 3D constructs to space to investigate diabetes treatments
November 10, 2022
Dispendix World Science Day for Peace & Development
October 13, 2022
Dispendix We are exhibiting at ASHG Annual Meeting
September 30, 2022
Bico The US senate has passed the FDA Modernization Act
Learn more

press releases

11/14/22RegulatoryNotice of extraordinary general meeting in BICO Group AB (publ)
11/10/22RegulatoryBICO Group announces new financial targets
11/09/22RegulatoryPublication of Interim Report January – September 2022
10/28/22RegulatoryBICO Group Nomination Committee 2023 AGM appointed
10/26/22Invitation to presentation of BICO’s Q3 results 2022
10/10/22Welcome to BICO Group’s Capital Markets Day 2022
08/24/22RegulatoryPublication of Interim Report January – June 2022
08/17/22Invitation to presentation of BICO’s Q2 results 2022
07/17/22Invitation to presentation of BICO’s preliminary Q2 performance 2022
07/15/22RegulatoryBICO announces preliminary financial performance for the second quarter
05/18/22RegulatoryBICO Publishes Interim Report January – March 2022: Continued growth in sales, improved profitability and focus on commercial synergies
05/12/22RegulatoryBICO Group adds senior IR manager to its executive management
05/11/22Invitation to presentation of BICO’s Q1 results 2022
05/06/22BICO acquires Allegro 3D, adding new light-based 3D bioprinting technology – complementing the existing offering of application tailored products
05/02/22RegulatoryBusiness update for BICO Group AB (publ)
04/29/22New Interim CFO at BICO
04/27/22BICO's Board of Directors: "Full confidence in the CEO, management and current strategic direction"
04/26/22RegulatoryBulletin from Annual General Meeting in BICO Group AB (publ)
04/26/22BICO's CFO Gusten Danielsson leaves his assignment
04/20/22The BICO Group has been awarded 7 iF design awards for excellence in product design
03/31/22BICO Companies win Red Dot Design Award for Outstanding Product Design
03/25/22MatTek Announces Production and Shipping of EpiOral Tissues from European Facility to Better Service the Wider Market
03/24/22RegulatoryNotice to Attend the Annual General Meeting in BICO Group AB (Publ)
03/23/22MatTek Enters Distribution Agreement and Strategic Partnership with Cell4Pharma
03/16/22RegulatoryBICO publishes Annual Report 2021
03/09/22Nanoscribe introduces Extra Large Feature Print Set to extend 3D Microfabrication capabilities to print centimetre-sized structures
03/03/22Cellenion Announces Opening of BICO’s First Single Cell Analysis Centre of Excellence
03/02/22SCIENION Announces Study Results for PoC-BoSens, an Optofluidic-based Infectious Disease Diagnostic Platform
03/01/22CELLINK Launches the BIO CELLX, a First of its Kind Biodispensing Platform to Automate 3D Cell Culture
02/28/22RegulatoryBICO Group AB (publ) announces an increase in number of shares and votes
02/23/22BICO has reached a beneficial and sustainable solution with Organovo
02/23/22RegulatoryYear-end report 2021: Strong growth, positive EBITDA, and a clear plan for increased profitability
02/22/22Biosero Expands Laboratory Automation Capabilities with New Product Launches
02/17/22MatTek’s Lab-Grown Human Tissues Head to Space.
02/16/22CELLINK and CollPlant Enter a Collaboration Agreement to Explore Future Large-Scale Production of CollPlant's Regenerative Breast Implants using CELLINK's Bioprinting technologies.
02/16/22Invitation to earnings call for Year-end report 2021
02/03/22Biosero Joins Genedata Ready-to-Run Program to Streamline Lab Automation and Data Analysis
02/02/22DISPENDIX to Introduce Two Disruptive Liquid Handling Platforms at SLAS 2022
01/31/22BICO Group AB (publ) announces an increase in number of shares and votes
01/25/22Nanoscribe Launches Quantum X align, a high-precision 3D Printer Enabling Auto-Aligned Printing on Optical Fibers and Photonic Chips
01/19/22SCIENION Partners with Institute for Prevention and Occupational Medicine (IPA) to Develop UROfast, a Rapid Bladder Cancer Diagnostics Platform
01/13/22BICO Partners with the Center for Contemporary Sciences to Reduce Animal Testing in Life Sciences
01/11/22Statement from BICO regarding counterclaims in patent lawsuit by Organovo against group company CELLINK
12/28/21BICO completes the acquisition of Biosero
12/20/21BICO moves to Nasdaq Stockholm’s Large Cap Segment
12/16/21BICO invites to a teleconference about the acquisition of Biosero
12/16/21RegulatoryBICO has entered into an agreement to acquire Biosero, a leading software provider for automated workflows and laboratory connectivity
12/15/21CELLINK and Nanoscribe join forces to launch the Quantum X bio, the world’s most accurate 3D bioprinter
Learn more

FINANCIAL REPORTS

Learn more

Calendar